atopic dermatitis

Dermatology’s 2017 Game ChangersSeveral dermatologists go over what they're most excited about to see in 2017 in a number of different topics ranging from AD treatment to off-label technology use, to more male patients.
December Clinical Considerations for NPs, PAsIn this month's Clinical Considerations, we take a look at AD and bullying, whether or not derms are doing enough for psoriasis patients, and the potential of Epicutaneous immunotherapy.
Novel immunomodulators expected to usher in new therapeutic eraA number of systemic and topical treatments for atopic dermatitis are being developed that feature novel mechanisms of action targeting the inflammatory axes involved in the disease.
Study offers new insight into pediatric eczemaResearchers have identified the skin phenotype of pediatric atopic dermatitis (AD) — a finding that challenges the notion of filaggrin's central role in the disease.
Advances in pediatric inflammatory skin diseaseExciting research is likely to change treatment for children. Dr. Eichenfield discusses advancements in treating this population.
Phase 3 results demonstrate dupilumab efficacyNew data suggests positive safety and efficacy profile. Further studies need to assess long-term use.
Infant’s disseminated rash is twice misdiagnosedA frustrated mother carries her 2-month-old son into the office for evaluation of a diffuse bright red rash with dramatic hypopigmentation. Scalp, neck, axillary, and diaper areas are involved.
Knowledge of skin microbiome provides insights into dermatological conditionsDirect sequencing data, together with culture data, supplies researchers with information about communities of bacteria and fungi on the skin.
Study offers new insight into pediatric eczema
Study offers new insight into pediatric eczemaResearchers have identified the skin phenotype of pediatric atopic dermatitis (AD) — a finding that challenges the notion of filaggrin's central role in the disease.
October clinical considerations for NPs, PAsThis month, we examine how to recognize Zika virus, a new therapeutic option for AD, and the concept of field cancerization in treating actinic keratosis.